TRACON Pharmaceuticals Inc. (TCON)

0.65
0.02 3.49
NASDAQ : Health Technology
Prev Close 0.63
Open 0.63
Day Low/High 0.63 / 0.67
52 Wk Low/High 0.50 / 3.05
Volume 104.82K
Avg Volume 310.90K
Exchange NASDAQ
Shares Outstanding 29.90M
Market Cap 19.14M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TRACON Pharmaceuticals Presents Updated Data From Phase 1b/2 Study Of TRC105 And Votrient® In Patients With Soft Tissue Sarcoma Including Angiosarcoma

TRACON Pharmaceuticals Presents Updated Data From Phase 1b/2 Study Of TRC105 And Votrient® In Patients With Soft Tissue Sarcoma Including Angiosarcoma

Combination Treatment Continues to Demonstrate Encouraging Signs of Activity

TRACON Pharmaceuticals Announces Positive Results From National Cancer Institute Phase 1/2 Trial Of TRC105 And Nexavar® In Hepatocellular Cancer Published In Clinical Cancer Research

TRACON Pharmaceuticals Announces Positive Results From National Cancer Institute Phase 1/2 Trial Of TRC105 And Nexavar® In Hepatocellular Cancer Published In Clinical Cancer Research

Overall response rate of 25% by RECIST and median overall survival of 15.5 months exceeds response rate and median overall survival reported in pivotal trials of single agent Nexavar